On August 19, 2026, the FDA authorized the first autonomous robotic blood-draw device. It uses imaging and software to locate a good vein, insert the needle, collect the samples, and finish the draw, all under clinician supervision. The FDA framed it as a response to one of the most common procedures in healthcare, at a time when trained phlebotomists are in short supply.
The same roundup flags a few related med-tech moves: the FDA released a discussion paper on how to regulate generative AI-enabled medical devices, with comments due October 19, and Medicare proposed a “RAPID” pathway that would start the coverage process the same day a breakthrough device gets FDA authorization.
